{"id":344769,"date":"2025-08-24T13:50:23","date_gmt":"2025-08-24T13:50:23","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-avidity-biosciences\/"},"modified":"2025-08-24T13:50:23","modified_gmt":"2025-08-24T13:50:23","slug":"how-to-buy-avidity-biosciences","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/","title":{"rendered":"Avidity Biosciences, Inc. (RNA) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Avidity Biosciences, Inc. (RNA) Hisse Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334018,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-344769","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Avidity Biosciences, Inc. (RNA) Hisseleri Nas\u0131l Al\u0131n\u0131r - RNA Hisse Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Avidity Biosciences, Inc. (RNA) Hisseleri Nas\u0131l Al\u0131n\u0131r - RNA Hisse Yat\u0131r\u0131m\u0131"},"description":"Mevcut fiyat analizi, 2025-2030 tahminleri ve biyoteknoloji f\u0131rsatlar\u0131 i\u00e7in ad\u0131m ad\u0131m yat\u0131r\u0131m stratejileri ile Avidity Biosciences (RNA) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Mevcut fiyat analizi, 2025-2030 tahminleri ve biyoteknoloji f\u0131rsatlar\u0131 i\u00e7in ad\u0131m ad\u0131m yat\u0131r\u0131m stratejileri ile Avidity Biosciences (RNA) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 \u00f6\u011frenin."},"intro":"Patlayan RNA terap\u00f6tikleri devrimine kat\u0131lmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Avidity Biosciences \u015fu anda biyoteknolojideki en heyecan verici f\u0131rsatlardan birini temsil ediyor. Ufukta \u00fc\u00e7 potansiyel FDA onay\u0131 ve nadir n\u00f6rom\u00fcsk\u00fcler hastal\u0131klar\u0131 hedefleyen \u00e7\u0131\u011f\u0131r a\u00e7an teknoloji ile bu \u015firket, \u00f6nemli b\u00fcy\u00fcme i\u00e7in biletiniz olabilir. RNA hisselerine yat\u0131r\u0131m yaparken bilmeniz gereken her \u015feyi detayland\u0131ral\u0131m.","intro_source":{"label":"Intro","type":"text","formatted_value":"Patlayan RNA terap\u00f6tikleri devrimine kat\u0131lmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Avidity Biosciences \u015fu anda biyoteknolojideki en heyecan verici f\u0131rsatlardan birini temsil ediyor. Ufukta \u00fc\u00e7 potansiyel FDA onay\u0131 ve nadir n\u00f6rom\u00fcsk\u00fcler hastal\u0131klar\u0131 hedefleyen \u00e7\u0131\u011f\u0131r a\u00e7an teknoloji ile bu \u015firket, \u00f6nemli b\u00fcy\u00fcme i\u00e7in biletiniz olabilir. RNA hisselerine yat\u0131r\u0131m yaparken bilmeniz gereken her \u015feyi detayland\u0131ral\u0131m."},"body_html":"<h2>\ud83d\udcc8 Mevcut Piyasa Konumu ve Fiyat Analizi<\/h2> <p>24 A\u011fustos 2025 itibar\u0131yla, Avidity Biosciences (RNA) hisseleri <strong>46,35 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Bu, y\u0131lba\u015f\u0131ndan bu yana %<strong>59,39<\/strong> gibi dikkat \u00e7ekici bir performans\u0131 ve sadece ge\u00e7en ayda %<strong>36,65<\/strong>\u2019lik etkileyici bir art\u0131\u015f\u0131 temsil ediyor.<\/p> <p><strong>\u00d6nemli Tarih Uyar\u0131s\u0131:<\/strong> Takviminize <strong>6 Kas\u0131m 2025<\/strong> tarihini i\u015faretleyin - Avidity\u2019nin bir sonraki \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayaca\u011f\u0131 g\u00fcn. Tarihsel olarak, bu raporlar \u00f6nemli fiyat hareketlerine neden olmu\u015ftur. 7 A\u011fustos 2025\u2019teki son kazan\u00e7 raporu, gelir beklentilerini %139 oran\u0131nda a\u015ft\u0131 (3,85M $ ger\u00e7ekle\u015fen vs 1,61M $ tahmin), ancak hisse ba\u015f\u0131 kazan\u00e7 (EPS) %30 oran\u0131nda beklentinin alt\u0131nda kald\u0131 (-1,21 $ vs -0,93 $ tahmin).<\/p> <h3>Tarihsel Kazan\u00e7 Etkisi Analizi<\/h3> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><th>S\u00fcre<\/th><\/tr> <\/thead> <tbody> <tr><td>7 A\u011fu 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7<\/td><td>42,10 $<\/td><td>%10,1 Art\u0131\u015f (1 hafta)<\/td><td>Gelir beklentisi a\u015f\u0131ld\u0131<\/td><\/tr> <tr><td>8 May 2025<\/td><td>1. \u00c7eyrek Kazan\u00e7<\/td><td>38,75 $<\/td><td>%8,7 Art\u0131\u015f (3 g\u00fcn)<\/td><td>G\u00fc\u00e7l\u00fc \u00fcr\u00fcn hatt\u0131 g\u00fcncellemesi<\/td><\/tr> <tr><td>6 \u015eub 2025<\/td><td>2024 4. \u00c7eyrek<\/td><td>35,20 $<\/td><td>%15,2 Art\u0131\u015f (2 hafta)<\/td><td>FDA \u00e7\u0131\u011f\u0131r a\u00e7an haber<\/td><\/tr> <tr><td>7 Kas 2024<\/td><td>3. \u00c7eyrek Kazan\u00e7<\/td><td>32,80 $<\/td><td>%4,3 D\u00fc\u015f\u00fc\u015f (EPS beklentisi ka\u00e7t\u0131)<\/td><td>Klinik gecikme endi\u015feleri<\/td><\/tr> <tr><td>8 A\u011fu 2024<\/td><td>2. \u00c7eyrek 2024<\/td><td>29,50 $<\/td><td>%12,8 Art\u0131\u015f (1 hafta)<\/td><td>Olumlu deneme verileri<\/td><\/tr> <tr><td>9 May 2024<\/td><td>1. \u00c7eyrek 2024<\/td><td>26,10 $<\/td><td>%18,4 Art\u0131\u015f (s\u00fcrd\u00fcr\u00fclebilirlik anla\u015fmas\u0131)<\/td><td>Ortakl\u0131k duyurusu<\/td><\/tr> <\/tbody> <\/table> <p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc:<\/strong> Olumlu klinik g\u00fcncellemeler ve d\u00fczenleyici d\u00f6n\u00fcm noktalar\u0131 genellikle %10-20 kazan\u00e7 sa\u011flarken, kazan\u00e7 beklentilerinin ka\u00e7mas\u0131 ge\u00e7ici %3-5 d\u00fc\u015f\u00fc\u015flere yol a\u00e7ar ve genellikle \u00fcr\u00fcn hatt\u0131n\u0131n g\u00fcc\u00fcyle h\u0131zla toparlan\u0131r.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu (\u015eubat-A\u011fustos 2025)<\/h2> <p>RNA hisseleri bu d\u00f6nemde ola\u011fan\u00fcst\u00fc bir <strong>%59,39<\/strong> getiri sa\u011flad\u0131:<\/p> <p><strong>\u015eubat:<\/strong> 29,10 $ (tatil sonras\u0131 konsolidasyon)<br> <strong>Mart:<\/strong> 33,75 $ (FDA \u00e7\u0131\u011f\u0131r a\u00e7an terapi tan\u0131m\u0131 heyecan\u0131)<br> <strong>May\u0131s:<\/strong> 38,90 $ (Faz 3 kay\u0131t tamamlanma haberi)<br> <strong>Temmuz:<\/strong> 42,15 $ (2. \u00e7eyrek kazan\u00e7 haz\u0131rl\u0131\u011f\u0131)<br> <strong>A\u011fustos:<\/strong> 46,35 $ (g\u00fc\u00e7l\u00fc kazan\u00e7 a\u015f\u0131m\u0131 ve BLA sunum zamanlamas\u0131 teyidi)<\/p> <p>Bu y\u00fckseli\u015fi tetikleyen fakt\u00f6rler:<\/p> <ul> <li>Temmuz 2025\u2019te del-zota i\u00e7in FDA \u00c7\u0131\u011f\u0131r A\u00e7an Terapi tan\u0131m\u0131<\/li> <li>DM1 tedavisi i\u00e7in Faz 3 HARBOR denemesinin kay\u0131t tamamlanmas\u0131<\/li> <li>2027 ortalar\u0131na kadar uzanan 1,2 milyar $ g\u00fc\u00e7l\u00fc nakit pozisyonu<\/li> <li>12 ay i\u00e7inde planlanan \u00fc\u00e7 potansiyel BLA sunumu<\/li> <\/ul> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p><strong>2025 Y\u0131l Sonu:<\/strong> 65-75 $ (BLA sunum kataliz\u00f6r\u00fc) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><br> <strong>2026:<\/strong> 85-110 $ (ilk ticari lansman potansiyeli)<br> <strong>2028:<\/strong> 120-160 $ (\u00e7oklu \u00fcr\u00fcn gelir ak\u0131\u015flar\u0131)<br> <strong>2030:<\/strong> 180-250 $ (k\u00fcresel pazar geni\u015flemesi ve platform do\u011frulamas\u0131)<\/p> <p><strong>Sonu\u00e7:<\/strong> K\u0131sa vadeli kataliz\u00f6rlerle ola\u011fan\u00fcst\u00fc uzun vadeli b\u00fcy\u00fcme potansiyeli. Biyoteknolojiye maruz kalmak isteyen risk tolerans\u0131 y\u00fcksek yat\u0131r\u0131mc\u0131lar i\u00e7in ideal.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Olumlu Sinyaller<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>Klinik deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131 riski<\/strong> - Herhangi bir olumsuz sonu\u00e7 hisseleri %50-70 d\u00fc\u015f\u00fcrebilir<\/li> <li><strong>FDA reddi olas\u0131l\u0131\u011f\u0131<\/strong> - \u00c7\u0131\u011f\u0131r A\u00e7an stat\u00fcs\u00fcne ra\u011fmen onay garantisi yoktur<\/li> <li><strong>Nakit yakma endi\u015feleri<\/strong> - \u00c7eyreklik 157,3M $ zarar devam eden finansman gerektirir<\/li> <li><strong>Y\u00fcksek de\u011ferleme<\/strong> - 448 P\/S oran\u0131 primli fiyatlamay\u0131 g\u00f6sterir<\/li> <li><strong>Biyoteknoloji volatilitesi<\/strong> - 52 haftal\u0131k aral\u0131k 24,08 $-52,50 $ aras\u0131nda a\u015f\u0131r\u0131 dalgalanmalar<\/li> <\/ul> <h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>FDA \u00c7\u0131\u011f\u0131r A\u00e7an tan\u0131m\u0131<\/strong> - del-zota i\u00e7in h\u0131zland\u0131r\u0131lm\u0131\u015f onay yolu<\/li> <li><strong>\u00dc\u00e7 BLA sunumu<\/strong> - 2025 4. \u00e7eyrekten ba\u015flayarak 12 ay i\u00e7inde planland\u0131<\/li> <li><strong>1,2 milyar $ nakit runway<\/strong> - 2027 ortalar\u0131na kadar finansman sa\u011fland\u0131<\/li> <li><strong>\u0130lk ticari lansman<\/strong> - 2026\u2019da potansiyel gelir \u00fcretimi<\/li> <li><strong>Platform do\u011frulamas\u0131<\/strong> - Birden fazla programda tutarl\u0131 veriler<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> - Portf\u00f6y\u00fcn\u00fcz\u00fcn sadece %2-5\u2019ini y\u00fcksek riskli biyoteknolojiye ay\u0131r\u0131n<\/li> <li><strong>Dolar maliyeti ortalamas\u0131 yap\u0131n<\/strong> - Ayl\u0131k 500-1000 $ aras\u0131 al\u0131mlar yap\u0131n<\/li> <li><strong>Kas\u0131m uyar\u0131lar\u0131 kurun<\/strong> - Kazan\u00e7 sonras\u0131 f\u0131rsatlar\u0131 izleyin<\/li> <li><strong>Zamanlamay\u0131 \u00e7e\u015fitlendirin<\/strong> - Hem BLA \u00f6ncesi hem onay sonras\u0131 giri\u015f noktalar\u0131n\u0131 de\u011ferlendirin<\/li> <\/ol> <p><em>Mizahi t\u00fcccar bilgeli\u011fi:<\/em> \"RNA hisseleriyle ticaret yapmak, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir - heyecan verici potansiyel, ancak risk tolerans\u0131n\u0131z\u0131 yan\u0131n\u0131za al\u0131n ve FDA 'Evet' demeden d\u00fc\u011f\u00fcn fonunu riske atmay\u0131n.\"<\/p> <h2>\u2705 Avidity Biosciences, Inc. (RNA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir ticaret platformu se\u00e7in<\/td><td>NASDAQ eri\u015fimi ve biyoteknoloji hisseleri sunmas\u0131na dikkat edin<\/td><\/tr> <tr><td>2<\/td><td>Hesap fonlamas\u0131n\u0131 tamamlay\u0131n<\/td><td>Y\u00f6netilebilir bir miktarla ba\u015flay\u0131n (500-2000 $)<\/td><\/tr> <tr><td>3<\/td><td>\"RNA\" sembol\u00fcn\u00fc aray\u0131n<\/td><td>\u015eirket ad\u0131 de\u011fil, tam sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Sipari\u015f t\u00fcr\u00fcn\u00fc se\u00e7in<\/td><td>45-47 $ aral\u0131\u011f\u0131nda limit emri \u00f6nerilir<\/td><\/tr> <tr><td>5<\/td><td>\u00dccretleri g\u00f6zden ge\u00e7irin ve onaylay\u0131n<\/td><td>\u0130\u015flemlerde %0,5\u2019in alt\u0131nda komisyon hedefleyin<\/td><\/tr> <tr><td>6<\/td><td>Fiyat uyar\u0131lar\u0131 kurun<\/td><td>42-44 $ aral\u0131\u011f\u0131nda giri\u015f f\u0131rsatlar\u0131n\u0131 izleyin<\/td><\/tr> <tr><td>7<\/td><td>\u00c7\u0131k\u0131\u015f stratejisi planlay\u0131n<\/td><td>65-75 $ hedeflerinde kar almay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/td><\/tr> <tr><td>8<\/td><td>Haberleri d\u00fczenli takip edin<\/td><td>FDA kararlar\u0131 bu hisseyi dramatik \u015fekilde hareket ettirir<\/td><\/tr> <tr><td>9<\/td><td>Stratejik olarak yeniden yat\u0131r\u0131m yap\u0131n<\/td><td>Olumlu klinik g\u00fcncellemeler sonras\u0131 ekleme yapmay\u0131 de\u011ferlendirin<\/td><\/tr> <tr><td>10<\/td><td>Perspektifinizi koruyun<\/td><td>Biyoteknoloji 3-5 y\u0131ll\u0131k yat\u0131r\u0131m ufku gerektirir<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Neden Pocket Option Biyoteknoloji Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Uygun?<\/h2> <p>Biyoteknoloji ticaret stratejilerini test etmek isteyenler i\u00e7in Pocket Option benzersiz avantajlar sunar:<\/p> <ul> <li><strong>Minimum depozito sadece 5 $<\/strong> - Biyoteknoloji volatilitesini \u00f6nemli risk olmadan pratik yapmak i\u00e7in ideal<\/li> <li><strong>H\u0131zl\u0131 KYC s\u00fcreci<\/strong> - Tek belge do\u011frulamas\u0131 ile dakikalar i\u00e7inde ticarete ba\u015flay\u0131n<\/li> <li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong> - Karlar\u0131n\u0131za \u00e7e\u015fitli kanallardan eri\u015fim esnekli\u011fi<\/li> <li><strong>Ger\u00e7ek zamanl\u0131 NASDAQ verisi<\/strong> - Biyoteknoloji haberlerine zaman\u0131nda tepki vermek i\u00e7in gerekli<\/li> <\/ul> <p>Platformun d\u00fc\u015f\u00fck giri\u015f engeli, RNA gibi volatil biyoteknoloji hisselerine b\u00fcy\u00fck miktarlar yat\u0131rmadan \u00f6nce g\u00fcven olu\u015fturmak i\u00e7in idealdir.<\/p> <h2>\ud83c\udf0d 2025\u2019te Avidity: RNA Terap\u00f6tikleri \u00d6nc\u00fcs\u00fc<\/h2> <p>Avidity Biosciences, \u00e7\u0131\u011f\u0131r a\u00e7an Antikor Oligon\u00fckleotid Konjugat\u0131 (AOC\u2122) platformu ile RNA devriminin \u00f6n saflar\u0131nda yer al\u0131yor. \u015eirket, tarihsel olarak tedavi edilemeyen nadir n\u00f6rom\u00fcsk\u00fcler hastal\u0131klar\u0131 hedefliyor; Duchenne kas distrofisi, miyotonik distrofi tip 1 ve fasioskapulohumeral kas distrofisi dahil.<\/p> <p><strong>Mevcut piyasa konumu:<\/strong> 5,96 milyar $ piyasa de\u011feri ve ge\u00e7 a\u015fama geli\u015ftirmede \u00fc\u00e7 program. \u015eirketin <a href=\"https:\/\/www.stocktitan.net\/news\/RNA\/avidity-biosciences-reports-second-quarter-2025-financial-results-gf3f9hk9ngd8.html\">son finansal sonu\u00e7lar\u0131<\/a>, 2027 ortalar\u0131na kadar uzanan sa\u011flam nakit rezervlerini g\u00f6steriyor ve k\u00fcresel ticari lansman haz\u0131rl\u0131klar\u0131n\u0131 m\u00fcmk\u00fcn k\u0131l\u0131yor.<\/p> <p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek:<\/strong> Avidity\u2019nin ara\u015ft\u0131rma ekibi, AOC platformunun RNA terap\u00f6tiklerini kas dokusuna e\u015fi benzeri g\u00f6r\u00fclmemi\u015f bir hassasiyetle ula\u015ft\u0131rabildi\u011fini ke\u015ffetti - b\u00fcy\u00fck molek\u00fcl ila\u00e7lar i\u00e7in daha \u00f6nce imkans\u0131z oldu\u011fu d\u00fc\u015f\u00fcn\u00fclen bir ba\u015far\u0131. Bu at\u0131l\u0131m, b\u00fcy\u00fck ila\u00e7 \u015firketlerinin ortakl\u0131k f\u0131rsatlar\u0131 aray\u0131\u015f\u0131n\u0131 \u00e7ekti.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Mevcut Piyasa Konumu ve Fiyat Analizi<\/h2>\n<p>24 A\u011fustos 2025 itibar\u0131yla, Avidity Biosciences (RNA) hisseleri <strong>46,35 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Bu, y\u0131lba\u015f\u0131ndan bu yana %<strong>59,39<\/strong> gibi dikkat \u00e7ekici bir performans\u0131 ve sadece ge\u00e7en ayda %<strong>36,65<\/strong>\u2019lik etkileyici bir art\u0131\u015f\u0131 temsil ediyor.<\/p>\n<p><strong>\u00d6nemli Tarih Uyar\u0131s\u0131:<\/strong> Takviminize <strong>6 Kas\u0131m 2025<\/strong> tarihini i\u015faretleyin &#8211; Avidity\u2019nin bir sonraki \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayaca\u011f\u0131 g\u00fcn. Tarihsel olarak, bu raporlar \u00f6nemli fiyat hareketlerine neden olmu\u015ftur. 7 A\u011fustos 2025\u2019teki son kazan\u00e7 raporu, gelir beklentilerini %139 oran\u0131nda a\u015ft\u0131 (3,85M $ ger\u00e7ekle\u015fen vs 1,61M $ tahmin), ancak hisse ba\u015f\u0131 kazan\u00e7 (EPS) %30 oran\u0131nda beklentinin alt\u0131nda kald\u0131 (-1,21 $ vs -0,93 $ tahmin).<\/p>\n<h3>Tarihsel Kazan\u00e7 Etkisi Analizi<\/h3>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<th>S\u00fcre<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>7 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7<\/td>\n<td>42,10 $<\/td>\n<td>%10,1 Art\u0131\u015f (1 hafta)<\/td>\n<td>Gelir beklentisi a\u015f\u0131ld\u0131<\/td>\n<\/tr>\n<tr>\n<td>8 May 2025<\/td>\n<td>1. \u00c7eyrek Kazan\u00e7<\/td>\n<td>38,75 $<\/td>\n<td>%8,7 Art\u0131\u015f (3 g\u00fcn)<\/td>\n<td>G\u00fc\u00e7l\u00fc \u00fcr\u00fcn hatt\u0131 g\u00fcncellemesi<\/td>\n<\/tr>\n<tr>\n<td>6 \u015eub 2025<\/td>\n<td>2024 4. \u00c7eyrek<\/td>\n<td>35,20 $<\/td>\n<td>%15,2 Art\u0131\u015f (2 hafta)<\/td>\n<td>FDA \u00e7\u0131\u011f\u0131r a\u00e7an haber<\/td>\n<\/tr>\n<tr>\n<td>7 Kas 2024<\/td>\n<td>3. \u00c7eyrek Kazan\u00e7<\/td>\n<td>32,80 $<\/td>\n<td>%4,3 D\u00fc\u015f\u00fc\u015f (EPS beklentisi ka\u00e7t\u0131)<\/td>\n<td>Klinik gecikme endi\u015feleri<\/td>\n<\/tr>\n<tr>\n<td>8 A\u011fu 2024<\/td>\n<td>2. \u00c7eyrek 2024<\/td>\n<td>29,50 $<\/td>\n<td>%12,8 Art\u0131\u015f (1 hafta)<\/td>\n<td>Olumlu deneme verileri<\/td>\n<\/tr>\n<tr>\n<td>9 May 2024<\/td>\n<td>1. \u00c7eyrek 2024<\/td>\n<td>26,10 $<\/td>\n<td>%18,4 Art\u0131\u015f (s\u00fcrd\u00fcr\u00fclebilirlik anla\u015fmas\u0131)<\/td>\n<td>Ortakl\u0131k duyurusu<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc:<\/strong> Olumlu klinik g\u00fcncellemeler ve d\u00fczenleyici d\u00f6n\u00fcm noktalar\u0131 genellikle %10-20 kazan\u00e7 sa\u011flarken, kazan\u00e7 beklentilerinin ka\u00e7mas\u0131 ge\u00e7ici %3-5 d\u00fc\u015f\u00fc\u015flere yol a\u00e7ar ve genellikle \u00fcr\u00fcn hatt\u0131n\u0131n g\u00fcc\u00fcyle h\u0131zla toparlan\u0131r.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu (\u015eubat-A\u011fustos 2025)<\/h2>\n<p>RNA hisseleri bu d\u00f6nemde ola\u011fan\u00fcst\u00fc bir <strong>%59,39<\/strong> getiri sa\u011flad\u0131:<\/p>\n<p><strong>\u015eubat:<\/strong> 29,10 $ (tatil sonras\u0131 konsolidasyon)<br \/> <strong>Mart:<\/strong> 33,75 $ (FDA \u00e7\u0131\u011f\u0131r a\u00e7an terapi tan\u0131m\u0131 heyecan\u0131)<br \/> <strong>May\u0131s:<\/strong> 38,90 $ (Faz 3 kay\u0131t tamamlanma haberi)<br \/> <strong>Temmuz:<\/strong> 42,15 $ (2. \u00e7eyrek kazan\u00e7 haz\u0131rl\u0131\u011f\u0131)<br \/> <strong>A\u011fustos:<\/strong> 46,35 $ (g\u00fc\u00e7l\u00fc kazan\u00e7 a\u015f\u0131m\u0131 ve BLA sunum zamanlamas\u0131 teyidi)<\/p>\n<p>Bu y\u00fckseli\u015fi tetikleyen fakt\u00f6rler:<\/p>\n<ul>\n<li>Temmuz 2025\u2019te del-zota i\u00e7in FDA \u00c7\u0131\u011f\u0131r A\u00e7an Terapi tan\u0131m\u0131<\/li>\n<li>DM1 tedavisi i\u00e7in Faz 3 HARBOR denemesinin kay\u0131t tamamlanmas\u0131<\/li>\n<li>2027 ortalar\u0131na kadar uzanan 1,2 milyar $ g\u00fc\u00e7l\u00fc nakit pozisyonu<\/li>\n<li>12 ay i\u00e7inde planlanan \u00fc\u00e7 potansiyel BLA sunumu<\/li>\n<\/ul>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p><strong>2025 Y\u0131l Sonu:<\/strong> 65-75 $ (BLA sunum kataliz\u00f6r\u00fc) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><br \/> <strong>2026:<\/strong> 85-110 $ (ilk ticari lansman potansiyeli)<br \/> <strong>2028:<\/strong> 120-160 $ (\u00e7oklu \u00fcr\u00fcn gelir ak\u0131\u015flar\u0131)<br \/> <strong>2030:<\/strong> 180-250 $ (k\u00fcresel pazar geni\u015flemesi ve platform do\u011frulamas\u0131)<\/p>\n<p><strong>Sonu\u00e7:<\/strong> K\u0131sa vadeli kataliz\u00f6rlerle ola\u011fan\u00fcst\u00fc uzun vadeli b\u00fcy\u00fcme potansiyeli. Biyoteknolojiye maruz kalmak isteyen risk tolerans\u0131 y\u00fcksek yat\u0131r\u0131mc\u0131lar i\u00e7in ideal.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Olumlu Sinyaller<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>Klinik deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131 riski<\/strong> &#8211; Herhangi bir olumsuz sonu\u00e7 hisseleri %50-70 d\u00fc\u015f\u00fcrebilir<\/li>\n<li><strong>FDA reddi olas\u0131l\u0131\u011f\u0131<\/strong> &#8211; \u00c7\u0131\u011f\u0131r A\u00e7an stat\u00fcs\u00fcne ra\u011fmen onay garantisi yoktur<\/li>\n<li><strong>Nakit yakma endi\u015feleri<\/strong> &#8211; \u00c7eyreklik 157,3M $ zarar devam eden finansman gerektirir<\/li>\n<li><strong>Y\u00fcksek de\u011ferleme<\/strong> &#8211; 448 P\/S oran\u0131 primli fiyatlamay\u0131 g\u00f6sterir<\/li>\n<li><strong>Biyoteknoloji volatilitesi<\/strong> &#8211; 52 haftal\u0131k aral\u0131k 24,08 $-52,50 $ aras\u0131nda a\u015f\u0131r\u0131 dalgalanmalar<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>FDA \u00c7\u0131\u011f\u0131r A\u00e7an tan\u0131m\u0131<\/strong> &#8211; del-zota i\u00e7in h\u0131zland\u0131r\u0131lm\u0131\u015f onay yolu<\/li>\n<li><strong>\u00dc\u00e7 BLA sunumu<\/strong> &#8211; 2025 4. \u00e7eyrekten ba\u015flayarak 12 ay i\u00e7inde planland\u0131<\/li>\n<li><strong>1,2 milyar $ nakit runway<\/strong> &#8211; 2027 ortalar\u0131na kadar finansman sa\u011fland\u0131<\/li>\n<li><strong>\u0130lk ticari lansman<\/strong> &#8211; 2026\u2019da potansiyel gelir \u00fcretimi<\/li>\n<li><strong>Platform do\u011frulamas\u0131<\/strong> &#8211; Birden fazla programda tutarl\u0131 veriler<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> &#8211; Portf\u00f6y\u00fcn\u00fcz\u00fcn sadece %2-5\u2019ini y\u00fcksek riskli biyoteknolojiye ay\u0131r\u0131n<\/li>\n<li><strong>Dolar maliyeti ortalamas\u0131 yap\u0131n<\/strong> &#8211; Ayl\u0131k 500-1000 $ aras\u0131 al\u0131mlar yap\u0131n<\/li>\n<li><strong>Kas\u0131m uyar\u0131lar\u0131 kurun<\/strong> &#8211; Kazan\u00e7 sonras\u0131 f\u0131rsatlar\u0131 izleyin<\/li>\n<li><strong>Zamanlamay\u0131 \u00e7e\u015fitlendirin<\/strong> &#8211; Hem BLA \u00f6ncesi hem onay sonras\u0131 giri\u015f noktalar\u0131n\u0131 de\u011ferlendirin<\/li>\n<\/ol>\n<p><em>Mizahi t\u00fcccar bilgeli\u011fi:<\/em> &#8220;RNA hisseleriyle ticaret yapmak, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir &#8211; heyecan verici potansiyel, ancak risk tolerans\u0131n\u0131z\u0131 yan\u0131n\u0131za al\u0131n ve FDA &#8216;Evet&#8217; demeden d\u00fc\u011f\u00fcn fonunu riske atmay\u0131n.&#8221;<\/p>\n<h2>\u2705 Avidity Biosciences, Inc. (RNA) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir ticaret platformu se\u00e7in<\/td>\n<td>NASDAQ eri\u015fimi ve biyoteknoloji hisseleri sunmas\u0131na dikkat edin<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap fonlamas\u0131n\u0131 tamamlay\u0131n<\/td>\n<td>Y\u00f6netilebilir bir miktarla ba\u015flay\u0131n (500-2000 $)<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;RNA&#8221; sembol\u00fcn\u00fc aray\u0131n<\/td>\n<td>\u015eirket ad\u0131 de\u011fil, tam sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Sipari\u015f t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>\n<td>45-47 $ aral\u0131\u011f\u0131nda limit emri \u00f6nerilir<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u00dccretleri g\u00f6zden ge\u00e7irin ve onaylay\u0131n<\/td>\n<td>\u0130\u015flemlerde %0,5\u2019in alt\u0131nda komisyon hedefleyin<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Fiyat uyar\u0131lar\u0131 kurun<\/td>\n<td>42-44 $ aral\u0131\u011f\u0131nda giri\u015f f\u0131rsatlar\u0131n\u0131 izleyin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>\u00c7\u0131k\u0131\u015f stratejisi planlay\u0131n<\/td>\n<td>65-75 $ hedeflerinde kar almay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>Haberleri d\u00fczenli takip edin<\/td>\n<td>FDA kararlar\u0131 bu hisseyi dramatik \u015fekilde hareket ettirir<\/td>\n<\/tr>\n<tr>\n<td>9<\/td>\n<td>Stratejik olarak yeniden yat\u0131r\u0131m yap\u0131n<\/td>\n<td>Olumlu klinik g\u00fcncellemeler sonras\u0131 ekleme yapmay\u0131 de\u011ferlendirin<\/td>\n<\/tr>\n<tr>\n<td>10<\/td>\n<td>Perspektifinizi koruyun<\/td>\n<td>Biyoteknoloji 3-5 y\u0131ll\u0131k yat\u0131r\u0131m ufku gerektirir<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Neden Pocket Option Biyoteknoloji Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Uygun?<\/h2>\n<p>Biyoteknoloji ticaret stratejilerini test etmek isteyenler i\u00e7in Pocket Option benzersiz avantajlar sunar:<\/p>\n<ul>\n<li><strong>Minimum depozito sadece 5 $<\/strong> &#8211; Biyoteknoloji volatilitesini \u00f6nemli risk olmadan pratik yapmak i\u00e7in ideal<\/li>\n<li><strong>H\u0131zl\u0131 KYC s\u00fcreci<\/strong> &#8211; Tek belge do\u011frulamas\u0131 ile dakikalar i\u00e7inde ticarete ba\u015flay\u0131n<\/li>\n<li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong> &#8211; Karlar\u0131n\u0131za \u00e7e\u015fitli kanallardan eri\u015fim esnekli\u011fi<\/li>\n<li><strong>Ger\u00e7ek zamanl\u0131 NASDAQ verisi<\/strong> &#8211; Biyoteknoloji haberlerine zaman\u0131nda tepki vermek i\u00e7in gerekli<\/li>\n<\/ul>\n<p>Platformun d\u00fc\u015f\u00fck giri\u015f engeli, RNA gibi volatil biyoteknoloji hisselerine b\u00fcy\u00fck miktarlar yat\u0131rmadan \u00f6nce g\u00fcven olu\u015fturmak i\u00e7in idealdir.<\/p>\n<h2>\ud83c\udf0d 2025\u2019te Avidity: RNA Terap\u00f6tikleri \u00d6nc\u00fcs\u00fc<\/h2>\n<p>Avidity Biosciences, \u00e7\u0131\u011f\u0131r a\u00e7an Antikor Oligon\u00fckleotid Konjugat\u0131 (AOC\u2122) platformu ile RNA devriminin \u00f6n saflar\u0131nda yer al\u0131yor. \u015eirket, tarihsel olarak tedavi edilemeyen nadir n\u00f6rom\u00fcsk\u00fcler hastal\u0131klar\u0131 hedefliyor; Duchenne kas distrofisi, miyotonik distrofi tip 1 ve fasioskapulohumeral kas distrofisi dahil.<\/p>\n<p><strong>Mevcut piyasa konumu:<\/strong> 5,96 milyar $ piyasa de\u011feri ve ge\u00e7 a\u015fama geli\u015ftirmede \u00fc\u00e7 program. \u015eirketin <a href=\"https:\/\/www.stocktitan.net\/news\/RNA\/avidity-biosciences-reports-second-quarter-2025-financial-results-gf3f9hk9ngd8.html\">son finansal sonu\u00e7lar\u0131<\/a>, 2027 ortalar\u0131na kadar uzanan sa\u011flam nakit rezervlerini g\u00f6steriyor ve k\u00fcresel ticari lansman haz\u0131rl\u0131klar\u0131n\u0131 m\u00fcmk\u00fcn k\u0131l\u0131yor.<\/p>\n<p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek:<\/strong> Avidity\u2019nin ara\u015ft\u0131rma ekibi, AOC platformunun RNA terap\u00f6tiklerini kas dokusuna e\u015fi benzeri g\u00f6r\u00fclmemi\u015f bir hassasiyetle ula\u015ft\u0131rabildi\u011fini ke\u015ffetti &#8211; b\u00fcy\u00fck molek\u00fcl ila\u00e7lar i\u00e7in daha \u00f6nce imkans\u0131z oldu\u011fu d\u00fc\u015f\u00fcn\u00fclen bir ba\u015far\u0131. Bu at\u0131l\u0131m, b\u00fcy\u00fck ila\u00e7 \u015firketlerinin ortakl\u0131k f\u0131rsatlar\u0131 aray\u0131\u015f\u0131n\u0131 \u00e7ekti.<\/p>\n"},"faq":[{"question":"Avidity Biosciences hisseleri nereden al\u0131nabilir?","answer":"NASDAQ borsas\u0131nda i\u015flem g\u00f6ren Avidity Biosciences (RNA) hisseleri, bir\u00e7ok \u00e7evrimi\u00e7i arac\u0131 kurum ve ticaret platformu \u00fczerinden sat\u0131n al\u0131nabilir."},{"question":"RNA hisseleri i\u00e7in en iyi yat\u0131r\u0131m stratejisi nedir?","answer":"Yat\u0131r\u0131mc\u0131lar k\u00fc\u00e7\u00fck ba\u015flay\u0131p dolar maliyeti ortalamas\u0131 yapmal\u0131, Kas\u0131m ay\u0131ndaki kazan\u00e7 raporlar\u0131n\u0131 takip etmeli ve hem BLA \u00f6ncesi hem de onay sonras\u0131 giri\u015f noktalar\u0131n\u0131 de\u011ferlendirmelidir."},{"question":"Avidity Biosciences\u2019in riskleri nelerdir?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131, FDA onay\u0131n\u0131n reddedilme ihtimali, y\u00fcksek nakit yakma oran\u0131 ve biyoteknoloji sekt\u00f6r\u00fcndeki volatilite ba\u015fl\u0131ca risklerdir."},{"question":"\u015eirketin 2025-2030 fiyat tahmini nedir?","answer":"2025 sonunda 65-75 $, 2026\u2019da 85-110 $, 2028\u2019de 120-160 $ ve 2030\u2019da 180-250 $ aral\u0131\u011f\u0131nda fiyatlar beklenmektedir."},{"question":"Pocket Option biyoteknoloji yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 KYC s\u00fcreci, \u00e7ok say\u0131da para \u00e7ekme y\u00f6ntemi ve ger\u00e7ek zamanl\u0131 NASDAQ verisi sunmas\u0131 nedeniyle biyoteknoloji yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in idealdir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Avidity Biosciences hisseleri nereden al\u0131nabilir?","answer":"NASDAQ borsas\u0131nda i\u015flem g\u00f6ren Avidity Biosciences (RNA) hisseleri, bir\u00e7ok \u00e7evrimi\u00e7i arac\u0131 kurum ve ticaret platformu \u00fczerinden sat\u0131n al\u0131nabilir."},{"question":"RNA hisseleri i\u00e7in en iyi yat\u0131r\u0131m stratejisi nedir?","answer":"Yat\u0131r\u0131mc\u0131lar k\u00fc\u00e7\u00fck ba\u015flay\u0131p dolar maliyeti ortalamas\u0131 yapmal\u0131, Kas\u0131m ay\u0131ndaki kazan\u00e7 raporlar\u0131n\u0131 takip etmeli ve hem BLA \u00f6ncesi hem de onay sonras\u0131 giri\u015f noktalar\u0131n\u0131 de\u011ferlendirmelidir."},{"question":"Avidity Biosciences\u2019in riskleri nelerdir?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131, FDA onay\u0131n\u0131n reddedilme ihtimali, y\u00fcksek nakit yakma oran\u0131 ve biyoteknoloji sekt\u00f6r\u00fcndeki volatilite ba\u015fl\u0131ca risklerdir."},{"question":"\u015eirketin 2025-2030 fiyat tahmini nedir?","answer":"2025 sonunda 65-75 $, 2026\u2019da 85-110 $, 2028\u2019de 120-160 $ ve 2030\u2019da 180-250 $ aral\u0131\u011f\u0131nda fiyatlar beklenmektedir."},{"question":"Pocket Option biyoteknoloji yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 KYC s\u00fcreci, \u00e7ok say\u0131da para \u00e7ekme y\u00f6ntemi ve ger\u00e7ek zamanl\u0131 NASDAQ verisi sunmas\u0131 nedeniyle biyoteknoloji yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in idealdir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Avidity Biosciences, Inc. (RNA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Avidity Biosciences, Inc. (RNA) Hisse Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avidity Biosciences, Inc. (RNA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Avidity Biosciences, Inc. (RNA) Hisse Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-24T13:50:23+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Avidity Biosciences, Inc. (RNA) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Avidity Biosciences, Inc. (RNA) Hisse Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-24T13:50:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/\"},\"wordCount\":20,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/\",\"name\":\"Avidity Biosciences, Inc. (RNA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Avidity Biosciences, Inc. (RNA) Hisse Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"datePublished\":\"2025-08-24T13:50:23+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avidity Biosciences, Inc. (RNA) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Avidity Biosciences, Inc. (RNA) Hisse Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Avidity Biosciences, Inc. (RNA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Avidity Biosciences, Inc. (RNA) Hisse Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/","og_locale":"tr_TR","og_type":"article","og_title":"Avidity Biosciences, Inc. (RNA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Avidity Biosciences, Inc. (RNA) Hisse Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-24T13:50:23+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Avidity Biosciences, Inc. (RNA) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Avidity Biosciences, Inc. (RNA) Hisse Yat\u0131r\u0131m\u0131","datePublished":"2025-08-24T13:50:23+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/"},"wordCount":20,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/","name":"Avidity Biosciences, Inc. (RNA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Avidity Biosciences, Inc. (RNA) Hisse Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","datePublished":"2025-08-24T13:50:23+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-avidity-biosciences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Avidity Biosciences, Inc. (RNA) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Avidity Biosciences, Inc. (RNA) Hisse Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":344766,"slug":"how-to-buy-avidity-biosciences","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Avidity Biosciences, Inc. (RNA) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Avidity Biosciences, Inc. (RNA)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-avidity-biosciences\/"},"pt_AA":{"locale":"pt_AA","id":344770,"slug":"how-to-buy-avidity-biosciences","post_title":"Como comprar a\u00e7\u00f5es da Avidity Biosciences, Inc. (RNA) - Investimento em a\u00e7\u00f5es da Avidity Biosciences, Inc. (RNA)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-avidity-biosciences\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/344769","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=344769"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/344769\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334018"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=344769"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=344769"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=344769"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}